![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NEXMED DEVELOPS ROOM TEMPERATURE FORMULATION OF ALPROX-TD FOR ERECTILE DYSFUNCTION
NEXMED DEVELOPS ROOM TEMPERATURE FORMULATION OF ALPROX-TD FOR ERECTILE DYSFUNCTION
August 9, 2006
NexMed, Inc., a developer of innovative treatments based on the NexACT technology, announced that it has confirmed the long term room temperature stability of Alprox-TD, the company's proprietary topical treatment for erectile dysfunction ("ED").
Market Wire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct